SCHEMBL2344642

SCHEMBL2344642

CC(C)[Si](OC1CN(OC(=O)OCc2ccccc2)CC(O)C1c1ccc(O)cc1)(C(C)C)C(C)C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
FABP7 O15540 1/20 0.34
FABP5 Q01469 1/20 0.34
CA12 O43570 1/20 0.34
AKR1B10 O60218 1/20 0.34
AKR1B1 P15121 1/20 0.34
CA4 P22748 1/20 0.34
CA6 P23280 1/20 0.34
CA5A P35218 1/20 0.34
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34
CA14 Q9ULX7 1/20 0.34
CA5B Q9Y2D0 1/20 0.34
GPBAR1 Q8TDU6 5/20 0.34
CTSK P43235 2/20 0.33
GRIN2B Q13224 2/20 0.33
MAPT P10636 1/20 0.33
HTR2C P28335 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2338938 0.85 SMN1; SMN2 (0.40) HPGDCTSKGRIN2BHTR2C
SCHEMBL4583118 0.85 SMN1; SMN2 (0.40) HPGDCTSKGRIN2BHTR2C
SCHEMBL2339602 0.77 MMP9 (0.43) FABP7FABP5GRIN2B
SCHEMBL2684607 0.77
SCHEMBL2344278 0.76 NPC1 (0.41) CTSKALDH1A1
SCHEMBL4583065 0.73 FAAH (0.37) CTSKGRIN2BMAPTALDH1A1
SCHEMBL1037741 0.73 NPC1 (0.39) LMNACTSK
SCHEMBL2683449 0.71 CHRM4 (0.42) MAPT
SCHEMBL2338156 0.71 CHRM4 (0.42) MAPT
SCHEMBL2683683 0.69 MAPT (0.41) HPGDMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776359-B1 PIPERIDINE DERIVATIVES AS RENIN INHIBITORS NOVARTIS AG (CH) 2011-08-24 EP disclosed
US-20080076766-A1 Piperidine Derivatives As Renin Inhibitor SPEEDEL EXPERIMENTA AG (CH) 2008-03-27 US disclosed
EP-1816122-A2 3,4,5-substituted piperidines as therapeutic compounds Speedel Experimenta AG (CH) 2007-08-08 EP disclosed
US-20070167433-A1 3,4,5-Substituted piperidines as therapeutic compounds SPEEDEL EXPERIMENTA AG (CH) 2007-07-19 US disclosed
EP-1776359-A2 PIPERIDINE DERIVATIVES AS RENIN INHIBITORS Speedel Experimenta AG (CH) 2007-04-25 EP disclosed
WO-2006005741-A2 PIPERDINE DERIVATIVES AS RENIN INHIBITORS SPEEDEL EXPERIMENTA AG (CH) 2006-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076766-A1 Piperidine Derivatives As Renin Inhibitor REN, AGTR1, ACE LMNA 572/4885HPGD 692/4885FABP7 3222/4885
US-20070167433-A1 3,4,5-Substituted piperidines as therapeutic compounds CTSD, CTSL, CTSZ LMNA 390/4885HPGD 2799/4885FABP7 2974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.